Analysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report $6.63 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Xenon Pharmaceuticals’ earnings, with estimates ranging from $500,000.00 to $12.75 million. Xenon Pharmaceuticals reported sales of $410,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 1,517.1%. The business is scheduled to issue its next earnings results on Thursday, November 2nd.

On average, analysts expect that Xenon Pharmaceuticals will report full year sales of $6.63 million for the current year, with estimates ranging from $13.27 million to $13.52 million. For the next fiscal year, analysts expect that the firm will report sales of $6.00 million per share. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.38 million.

A number of research analysts recently commented on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, June 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $5.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Zacks Investment Research raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $11.88.

Shares of Xenon Pharmaceuticals (XENE) opened at 3.05 on Tuesday. Xenon Pharmaceuticals has a one year low of $2.85 and a one year high of $9.95. The company’s market cap is $54.89 million. The firm’s 50-day moving average is $3.46 and its 200-day moving average is $5.32.

In other Xenon Pharmaceuticals news, insider Value Fund L. P. Biotechnology bought 85,461 shares of the firm’s stock in a transaction on Tuesday, June 27th. The shares were purchased at an average price of $4.00 per share, for a total transaction of $341,844.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Value Fund L. P. Biotechnology bought 20,411 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was acquired at an average price of $4.00 per share, for a total transaction of $81,644.00. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 490,978 shares of company stock worth $1,891,534. Company insiders own 9.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Endurant Capital Management LP acquired a new position in Xenon Pharmaceuticals during the first quarter worth about $1,363,000. Sabby Management LLC acquired a new position in Xenon Pharmaceuticals during the first quarter worth about $1,186,000. KCG Holdings Inc. acquired a new position in Xenon Pharmaceuticals during the first quarter worth about $122,000. Renaissance Technologies LLC boosted its position in Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares in the last quarter. Finally, K2 Principal Fund L.P. boosted its position in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares in the last quarter. Hedge funds and other institutional investors own 56.01% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/08/xenon-pharmaceuticals-inc-nasdaqxene-expected-to-post-quarterly-sales-of-6-63-million.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.